Quantcast
Last updated on April 24, 2014 at 5:50 EDT

Latest Golimumab Stories

2013-11-14 08:34:41

EU5 Payers Say a Novel Mechanism of Action is a Market Access Lever, But Comparative Clinical Data is Increasingly Key, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed rheumatologists across the EU5 (France, Germany, Italy, Spain and the United Kingdom) currently prescribe biologics--largely...

2013-10-28 08:29:30

Nearly 70 Percent of Patients Receiving SIMPONI ARIA at Two Years Demonstrated ACR 20 Response SAN DIEGO, Oct. 28, 2013 /PRNewswire/ -- New two-year results of a Phase 3 study sponsored by Janssen Research & Development, LLC (Janssen) showed that SIMPONI(®) ARIA(TM) (golimumab) for infusion in combination with methotrexate inhibited radiographic progression in patients with moderately to severely active rheumatoid arthritis (RA) at week 24, and continued to inhibit radiographic...

2013-10-09 12:26:03

Key Drivers of Market Growth Will Be the Uptake of Humira, Simponi, Vedolizumab and Tofacitinib, According to Findings from Decision Resources BURLINGTON, Mass., Oct. 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ulcerative colitis drug market will increase from $2.1 billion in 2012 to $3.6 billion in 2022 in the United States, France, Germany, Italy, Spain, the...

2013-07-18 20:22:30

First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis HORSHAM, Pa., July 18, 2013 /PRNewswire/ -- Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) approval of SIMPONI(®) ARIA(TM) (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate. SIMPONI ARIA, the only fully-human...

2013-06-12 08:28:58

Data from Three Pivotal Phase 3 Trials Presented at 2013 EULAR Annual Congress MADRID, June 12, 2013 /PRNewswire/ -- Janssen Biotech, Inc. announced today new five-year data from three pivotal Phase 3 studies evaluating SIMPONI(®) (golimumab) 50 mg administered subcutaneously once every four weeks in the treatment of moderately to severely active rheumatoid arthritis (RA). The new findings from open-label, long-term extensions of the pivotal registration trials are results from...

2013-05-15 16:28:06

First and Only Subcutaneous Biologic Treatment Approved to Induce and Maintain Clinical Response and Improve Endoscopic Appearance of the Mucosa During Induction HORSHAM, Pa., May 15, 2013 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI(®) (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have demonstrated corticosteroid dependence or who have had...

2012-11-12 08:27:53

WASHINGTON, Nov. 12, 2012 /PRNewswire/ -- New Phase 3 findings from a Janssen Research & Development, LLC (Janssen)-sponsored study showed treatment with the investigational intravenous (I.V.) therapy golimumab, a tumor necrosis factor (TNF) inhibitor, significantly inhibited radiographic progression in patients with active moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate. Analysis of study patients' X-rays showed significant inhibition of the progression...

2012-11-02 07:27:32

NEW BRUNSWICK, N.J., Nov. 2, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, November 10, at approximately 5:00 p.m., Eastern Time, to coincide with the American College of Rheumatology (ACR) Annual Meeting being held in Washington, D.C. The presentation will highlight new, pivotal Phase 3 study findings, including; Intravenous Golimumab Inhibits Radiographic Progression and...

2012-10-22 07:29:39

LAS VEGAS, Oct. 22, 2012 /PRNewswire/ -- New Phase 3 study findings showed significantly more patients with moderately to severely active ulcerative colitis (UC) who responded to induction therapy with subcutaneously administered SIMPONI(®) (golimumab) maintained clinical response through week 54, the primary endpoint of the study, compared with patients receiving placebo. Investigators will report clinical response, clinical remission and mucosal healing results through one year from...

2012-09-18 10:25:22

HORSHAM, Pa., Sept. 18, 2012 /PRNewswire/ -- Janssen Biotech, Inc. announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of an investigational intravenous formulation of the anti-tumor necrosis factor (TNF)-alpha SIMPONI(®) (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). An estimated 1.5 million Americans are living with RA,[1] a chronic autoimmune...